Skin Biopsy Market – Global Market Size, Strategic Growth Drivers, Risk Assessment Framework, Regulatory Landscape Review, Competitive Intensity Mapping & Long-Term Industry Outlook to 2032
Overview
The Skin Biopsy Market size was valued at USD 143.84 Million in 2025 and the total Skin Biopsy revenue is expected to grow at a CAGR of 6% from 2026 to 2032, reaching USD 216.29 Million by 2032.
The skin biopsy technique is an integral part of the diagnosis of skin cancer and other skin disorders, such as actinic keratosis, dermatitis, and psoriasis, among others. This technique involves the removal of a skin sample from a lesion or infection, which is then examined under a microscope to detect cancerous cells. Skin biopsy is not only a diagnostic tool for skin cancer, but it can also assist in the treatment of cancer by completely removing cancerous cells. Additionally, this technique is minimally invasive, causing small incisions to the skin, resulting in shorter recovery times. Due to the benefits offered by skin biopsy, it has gained immense popularity for the diagnosis of skin cancer.
The skin biopsy market is a significant part of the medical industry, driven by the increasing prevalence of skin cancer and the need for effective diagnostic tools. The market includes various companies, such as Stryker, which is a global leader in medical technology. Stryker offers innovative products and services in the Medical and Surgical, Neurotechnology, Orthopaedics, and Spine fields, with the aim of improving patient and healthcare outcome.
To know about the Research Methodology :- Request Free Sample Report
Competitive Landscapes:
The skin biopsy market is highly competitive, with various companies focusing on both organic and inorganic growth strategies to expand their customer base and increase their market share. Organic growth strategies such as product launches, product approvals, patents, and events are some of the ways in which companies are aiming to achieve growth. Inorganic growth strategies, including partnerships, collaborations, and acquisitions, have also been witnessed in the market, paving the way for business expansion.
For instance, in recent years, Guardant Health, Inc. has strengthened its collaboration with Epic, one of the most widely used comprehensive electronic health record (EHR) systems, to integrate its portfolio of cancer diagnostic tests with Epic’s healthcare platform. This integration improves clinical workflow efficiency, enables easier access to precision oncology testing for healthcare providers, and supports Guardant Health in expanding its customer reach while strengthening its competitive position in the advanced cancer diagnostics market.
In addition, regulatory approvals continue to play a crucial role in enhancing the market presence of companies operating in the biopsy diagnostics space. Guardant Health, Inc. received regulatory approval for Guardant360 CDx, a liquid biopsy test designed for tumor mutation profiling, from the Japanese Ministry of Health, Labour and Welfare (MHLW). This approval enables the company to expand its precision oncology diagnostics presence in Japan and strengthens its global positioning in advanced cancer diagnostic technologies.
Skin Biopsy Market Dynamics:
Rising Prevalence of Skin Cancer and Dermatological Disorders Driving the Skin Biopsy Market
The Skin Biopsy Market is experiencing steady growth due to the increasing prevalence of skin cancer and other dermatological disorders, which is raising the demand for skin biopsy as a primary diagnostic procedure. The growing incidence of melanoma and non-melanoma skin cancers has significantly increased the number of dermatological screening procedures globally. According to the American Academy of Dermatology Association, more than 1 million Americans are living with melanoma, and approximately 197,700 new melanoma cases are diagnosed in the United States annually. This rising disease burden is increasing the need for early and accurate diagnostic tools such as skin biopsy.
In addition, skin cancer diagnoses in the United States exceed the combined number of breast, prostate, lung, and colon cancer cases each year, further emphasizing the growing demand for dermatological diagnostic procedures. Apart from cancer detection, skin biopsy procedures are widely used to diagnose several dermatological conditions including actinic keratosis, dermatitis, psoriasis, and skin infections. The increasing incidence of these skin disorders is contributing to the rising procedural volume of skin biopsies across hospitals and dermatology clinics, supporting the overall growth of the Skin Biopsy Market.
Government and Institutional Awareness Programs Supporting Market Growth
The Skin Biopsy Market is also benefiting from increasing public awareness initiatives launched by governments and dermatology institutions to promote early detection and prevention of skin diseases. Several organizations are actively educating the population about the risks associated with excessive sun exposure, the importance of regular skin examinations, and early diagnosis of suspicious skin lesions.
For instance, the American Academy of Dermatology (AAD) conducts nationwide awareness campaigns and screening programs aimed at reducing the incidence and mortality associated with skin cancer. These initiatives focus on educating individuals about preventive measures, early symptom identification, and the importance of dermatological consultation. Similarly, the Canadian Dermatology Association promotes public awareness regarding sun protection and early detection strategies to reduce skin cancer risk.
Such initiatives are increasing public awareness about skin health and encouraging individuals to undergo dermatological screening and diagnostic procedures. As awareness and screening rates continue to rise, the demand for skin biopsy procedures and diagnostic instruments is expected to increase. Furthermore, these programs are encouraging investments in dermatology research and the development of advanced biopsy technologies, which will continue to support the expansion of the Skin Biopsy Market during the forecast period.
Skin Biopsy Market Segment Analysis:
Based on product type, the punch biopsy segment dominated the market in 2025 due to its high diagnostic accuracy and ability to collect deeper skin tissue samples for histopathological analysis. The growing prevalence of skin cancer and increasing dermatological diagnostic procedures are driving the demand for punch biopsy instruments. Additionally, the development of disposable and minimally invasive biopsy tools is supporting segment growth.
Based on device, Biopsy punches held the largest share in 2025 due to their widespread use in dermatology for accurate tissue sampling. The increasing demand for minimally invasive procedures and improvements in precision biopsy instruments are supporting market growth.
Based on indication, the Skin Biopsy Market is segmented into skin cancer, actinic keratosis, dermatitis, and others. The skin cancer segment dominated the market in 2025 due to the rising global prevalence of melanoma and non-melanoma skin cancers. Skin biopsy remains the most reliable diagnostic method for confirming malignant skin lesions, which continues to drive the demand for biopsy procedures.
Based on application, the Skin Biopsy Market is segmented into cancer diagnosis, infectious disease diagnosis, and autoimmune disorder diagnosis. Cancer diagnosis accounted for the largest share in 2025 due to the increasing focus on early detection of skin cancers and the growing number of dermatological diagnostic procedures worldwide.
Based on end users, the Skin Biopsy Market is segmented into hospitals, multispecialty clinics, diagnostic centers, and others. The hospitals segment dominated the market in 2025 due to the availability of advanced diagnostic infrastructure, specialized dermatology departments, and higher patient volumes for skin cancer screening and dermatological treatments.
Skin Biopsy Market Regional Insights:
North America held the largest share of the Skin Biopsy Market in 2025 and is expected to maintain its dominance during the forecast period. The United States dominated the regional market, while Canada is projected to grow at the fastest rate. The strong presence of major companies such as Integra LifeSciences, Becton, Dickinson and Company, and Innovia Medical supports market growth in this region. In addition, continuous advancements in biopsy instrument manufacturing and the rising prevalence of skin cancer cases in the U.S. are increasing the demand for skin biopsy procedures in hospitals and dermatology clinics.
Europe accounted for the second-largest share of the Skin Biopsy Market due to strong healthcare infrastructure, increasing dermatology diagnostic procedures, and rising awareness regarding early skin cancer detection across countries such as Germany, the UK, and France.
Asia Pacific is expected to grow at the highest rate during the forecast period due to the large patient population, improving healthcare infrastructure, and rising awareness regarding skin disease diagnosis in countries such as China, India, and Japan. South America is expected to witness steady growth, supported by improving healthcare access and increasing dermatological diagnostic procedures in countries such as Brazil and Mexico. Middle East & Africa is projected to grow gradually due to rising healthcare investments and expanding dermatology services in countries such as Saudi Arabia, the UAE, and South Africa.
Skin Biopsy Market Recent Developments (2025–2026):
| Exact Date | Company | Development | Impact |
|---|---|---|---|
| 26 February 2026 | Integra LifeSciences | The company implemented a simplified operating model and confirmed Integra Skin supply reliability as part of its 2025-2026 transformation plan. | This restructuring aims to improve execution and accountability, ensuring stable availability of high-demand skin tissue products for surgical and biopsy procedures. |
| 09 February 2026 | Becton, Dickinson and Company (BD) | The company successfully completed the spin-off of its Biosciences & Diagnostic Solutions business into an independent entity. | This strategic move allows BD to sharpen its focus on core medical technology while the new entity optimizes advanced diagnostic tools and biopsy equipment. |
| 21 October 2025 | Hologic, Inc. | The company entered into a definitive agreement to be acquired by Blackstone and TPG in a transaction valued at approximately USD 15.4 billion. | The acquisition is expected to provide Hologic with significant capital to expand its Interventional Breast Health and diagnostic biopsy portfolios globally. |
Skin Biopsy Market Scope: Inquiry Before Buying
| Skin Biopsy Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2032 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | 143.84 USD Billion |
| Forecast Period 2026-2032 CAGR: | 6% | Market Size in 2032: | 216.29 USD Billion |
| Segments Covered: | by Product Type | Shave Biopsy Punch Biopsy Excisional Biopsy Incisional Biopsy |
|
| by Device | Needle-Based Biopsy Guns Biopsy Curettes and Punches Guidance Systems Biopsy Forceps Biopsy Needles Others |
||
| by Indication | Skin Cancer Actinic Keratosis Dermatitis Psoriasis Skin Infection Others |
||
| by Application | Cancer Diagnosis Infectious Disease Diagnosis Autoimmune Disorder Diagnosis |
||
| by End-User | Hospitals Dermatology Clinics / Multispecialty Clinics Diagnostic Centers / Diagnostic Laboratories Research Institutions Others |
||
Global Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
South America (Brazil, Argentina, and Rest of South America)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
Skin Biopsy Market Key Players:
1. AccuTec, Inc.
2. Cardinal Health Inc.
3. Innovia Medical
4. Jai Surgicals Ltd.
5. Integra LifeSciences,
6. Vernacare,
7. Becton
8. Dickinson and Company
9. KAI Group
10. Paramount Surgimed Limited
11. Devicor Medical Products,Inc.
12. Gallini Srl
13. Hologic, Inc.
14. Boston Scientific Corporation
15. World Precision Instruments
16. Firefly
17. SkinIO
18. Canfield Scientific, Inc.
19. FotoFinder Systems, Inc.
20. 3Gen
21. MetaOptima
22. Agilent Technologies
23. SkinVision
24. Speclipse, Inc.
25. Skin Analytics